Platinum Chemotherapy, Not PARP Inhibitors, Emerges as the Main Driver of Blood Clone Expansion
New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous ...
New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous ...
A new study finds that homologous recombination deficiency scores show a surprising non-monotonic relationship with pathological response to short-course radiotherapy ...
A new review outlines how combining PARP inhibitors with immune checkpoint inhibitors can convert immunologically cold ovarian tumors into hot ...
New research links LINE-1 retrotransposon overexpression and homologous recombination deficiency in gastric cancer to heightened immune pathway activation and potential ...
A new Nature study integrates multiple classes of genomic mutations to define the distinct mutational processes that shape prostate cancer ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking study poised to reshape the landscape of precision oncology, researchers have conducted the largest pan-cancer analysis focusing ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine